These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma RP; Janicak PG; Bissette G; Nemeroff CB Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757 [TBL] [Abstract][Full Text] [Related]
30. Biological vulnerability to depression: replication of MAO and evoked potentials as risk factors. Haier RJ; Buchsbaum MS; DeMet E; Wu J Neuropsychobiology; 1988; 20(2):62-6. PubMed ID: 3253603 [TBL] [Abstract][Full Text] [Related]
31. Platelet monoamine oxidase activity in first-degree relatives of schizophrenic patients. Propping P; Friedl W Psychopharmacology (Berl); 1979 Nov; 65(3):265-72. PubMed ID: 117498 [TBL] [Abstract][Full Text] [Related]
32. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin. Maas JW; Contreras SA; Seleshi E; Bowden CL Arch Gen Psychiatry; 1988 Jun; 45(6):553-9. PubMed ID: 3377641 [TBL] [Abstract][Full Text] [Related]
33. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients. Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035 [TBL] [Abstract][Full Text] [Related]
34. Progressive brain changes in children and adolescents with first-episode psychosis. Arango C; Rapado-Castro M; Reig S; Castro-Fornieles J; González-Pinto A; Otero S; Baeza I; Moreno C; Graell M; Janssen J; Parellada M; Moreno D; Bargalló N; Desco M Arch Gen Psychiatry; 2012 Jan; 69(1):16-26. PubMed ID: 22213785 [TBL] [Abstract][Full Text] [Related]
35. Poor outcome and low platelet MAO activity in chronic schizophrenia. Bierer L; Docherty JP; Young JG; Giller E; Cohen D Am J Psychiatry; 1984 Feb; 141(2):257-60. PubMed ID: 6140867 [TBL] [Abstract][Full Text] [Related]
36. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329 [TBL] [Abstract][Full Text] [Related]
37. A comprehensive study of chronic schizophrenic patients. II: Biological, neuropsychological, and clinical correlates of CT abnormality. Pandurangi AK; Dewan MJ; Boucher M; Levy B; Ramachandran T; Bartell K; Bick PA; Phelps BH; Major L Acta Psychiatr Scand; 1986 Feb; 73(2):161-71. PubMed ID: 3705993 [TBL] [Abstract][Full Text] [Related]
38. Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders. Orsulak PJ; Schildkraut JJ; Schatzberg AF; Herzog JM Biol Psychiatry; 1978 Dec; 13(6):637-47. PubMed ID: 737252 [TBL] [Abstract][Full Text] [Related]
39. Human platelet MAO in drug-free and medicated schizophrenic patients. Friedhoff AJ; Miller JC; Weisenfreund J Am J Psychiatry; 1978 Aug; 135(8):952-5. PubMed ID: 27104 [TBL] [Abstract][Full Text] [Related]
40. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Issa F; Gerhardt GA; Bartko JJ; Suddath RL; Lynch M; Gamache PH; Freedman R; Wyatt RJ; Kirch DG Psychiatry Res; 1994 Jun; 52(3):237-49. PubMed ID: 7991718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]